2017

Request for Proposals: HSCI Seed Grant Program 2017

March 21, 2017

Harvard Stem Cell Institute (HSCI) invites applications for seed grant funding for its 2017 cycle. The purpose of this program is to provide funding for innovative projects in the field of stem cell and regenerative biology. As was the case last year, HSCI strongly encourages proposals with a translational focus, or which are otherwise poised to accelerate the development of new stem cell-based therapies or cures. However, proposals at all stages of development are welcome. HSCI intends to award up to ten grants in response to this request for proposals, contingent upon the number and...

Read more about Request for Proposals: HSCI Seed Grant Program 2017

Helping beta cells divide

March 17, 2017

 

Scientists identify a key barrier to proliferation of inuslin-producing cells

If you become resistant to insulin, a condition that is a precursor to type 2 diabetes, your body tries to compensate by producing more of the “beta” cells in the pancreas that produce the critical hormone. Researchers have long sought to understand why these cells often fail to proliferate in people who go on to develop the disease. Studying both humans and mice, scientists at Joslin Diabetes Center now have pinpointed one key biological mechanism that can prevent...

Read more about Helping beta cells divide
Sridhar Ramaswamy, MD

HSCI Alumni: Sridhar Ramaswamy, MD

Senior VP for Research and Development, Tesaro, Inc.

Metastatic cancers are the major reason for treatment failure in the clinic, but we lack a detailed understanding of how primary tumors metastasize, why these secondary tumors are relatively drug resistant, and what enables cancer cells to remain dormant and then cause disease relapse many years after apparently curative treatment. We are taking a multidisciplinary approach to attack these fundamental and related problems. Our major goal is to identify important cancer gene networks that are essential in human cancer progression, to guide the development and clinical use of new cancer drugs and diagnostics.... Read more about Sridhar Ramaswamy, MD

Pages